Bristol-Myers Squibb reads as an income name — Stocklytics 61/100, with a 3.9% dividend yield in the thesis. Under the hood: P/E 14.2, about 35% below its own multi-year median, plus 3.9% dividend yield.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Bullish (65+)Neutral (45–64)Bearish (<45)Fair value
Score Breakdown
Market percentile scores loading…
Value
64
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–
Growth
47
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–
Quality
72
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–
Financial Summary
Bristol-Myers Squibb Company (BMY) last printed $63.43. Equity value is $129.66B. Trailing earnings multiple 14.03. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
$19.43B
$20.78B
$22.56B
$26.14B
$42.52B
$46.38B
$46.16B
$45.01B
$48.3B
$48.2B
About
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Stocklytics score rationale: value 64, quality 72, growth 47.
AI Score 75. Bristol-Myers Squibb has a strong market cap of $127.71 billion and a solid net profit margin of approximately 18.5%, indicating good profitability. However, its high price-to-earnings ratio of about 13.82 and a price-to-book ratio of 5.45 suggest that it may be overvalued relative to its earnings and assets, which could limit upside potential
Summary
Bristol-Myers Squibb Company operates in Healthcare, within the Drug Manufacturers - General industry. Its overall score is 59.
Valuation
The shares have a P/E of 13.8 and a price-to-book ratio of 5.5. The value score is 64.
Quality
The quality score is 67, supported by a net margin of 18.5%. The dividend yield is 4.0%.
Growth
The growth score is 46, indicating growth is the weakest of the reported factor scores.
Risks
Growth is a relative concern given the growth score of 46. The price-to-book ratio of 5.5 may also be relevant when assessing valuation.
Fair value
BMY fair value $133.71. Price $63.43. Price is 53% below fair value.
Below fair value, but more expensive than usual. A smaller discount than on 77% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.
Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 28.3, a blend of the Drug Manufacturers - General median (35.7) and the stock's own 10-year median (20.8). How we calculate it →
Yield 3.97%. Payout ratio 55.38%. Frequency Quarterly.
Safety score 89/100 · Safe. Payout ratio is 55% of earnings. Dividends use less than 40% of free cash flow. Dividends were paid in 55 separate years. Yield is 4.0%, in a range that is usually sustainable.
Ex-date
Dividend
Record
Payment
Frequency
2026-10-02
$0.63
2026-10-02
2026-11-02
Quarterly
2026-07-02
$0.63
2026-07-02
2026-08-03
Quarterly
2026-04-02
$0.63
2026-04-02
2026-05-01
Quarterly
2026-01-02
$0.63
2026-01-02
2026-02-02
Quarterly
2025-10-03
$0.62
2025-10-03
2025-11-03
Quarterly
2025-07-03
$0.62
2025-07-03
2025-08-01
Quarterly
2025-04-04
$0.62
2025-04-04
2025-05-01
Quarterly
2025-01-03
$0.62
2025-01-03
2025-02-03
Quarterly
2024-10-04
$0.60
2024-10-04
2024-11-01
Quarterly
2024-07-05
$0.60
2024-07-05
2024-08-01
Quarterly
2024-04-04
$0.60
2024-04-05
2024-05-01
Quarterly
2024-01-04
$0.60
2024-01-05
2024-02-01
Quarterly
2023-10-05
$0.57
2023-10-06
2023-11-01
Quarterly
2023-07-06
$0.57
2023-07-07
2023-08-01
Quarterly
2023-04-06
$0.57
2023-04-10
2023-05-01
Quarterly
2023-01-05
$0.57
2023-01-06
2023-02-01
Quarterly
2022-10-06
$0.54
2022-10-07
2022-11-01
Quarterly
2022-06-30
$0.54
2022-07-01
2022-08-01
Quarterly
2022-03-31
$0.54
2022-04-01
2022-05-02
Quarterly
2022-01-06
$0.54
2022-01-07
2022-02-01
Quarterly
2021-09-30
$0.49
2021-10-01
2021-11-01
Quarterly
2021-07-01
$0.49
2021-07-02
2021-08-02
Quarterly
2021-03-31
$0.49
2021-04-01
2021-05-03
Quarterly
2020-12-31
$0.49
2021-01-04
2021-02-01
Quarterly
2020-10-01
$0.45
2020-10-02
2020-11-02
Quarterly
2020-07-02
$0.45
2020-07-06
2020-08-03
Quarterly
2020-04-02
$0.45
2020-04-03
2020-05-01
Quarterly
2020-01-02
$0.45
2020-01-03
2020-02-03
Quarterly
2019-10-03
$0.41
2019-10-04
2019-11-01
Quarterly
2019-07-03
$0.41
2019-07-05
2019-08-01
Quarterly
2019-04-04
$0.41
2019-04-05
2019-05-01
Quarterly
2019-01-03
$0.41
2019-01-04
2019-02-01
Quarterly
2018-10-04
$0.40
2018-10-05
2018-11-01
Quarterly
2018-07-05
$0.40
2018-07-06
2018-08-01
Quarterly
2018-04-05
$0.40
2018-04-06
2018-05-01
Quarterly
2018-01-04
$0.40
2018-01-05
2018-02-01
Quarterly
2017-10-05
$0.39
2017-10-06
2017-11-01
Quarterly
2017-07-05
$0.39
2017-07-07
2017-08-01
Quarterly
2017-04-05
$0.39
2017-04-07
2017-05-01
Quarterly
2017-01-04
$0.39
2017-01-06
2017-02-01
Quarterly
2016-10-05
$0.38
2016-10-07
2016-11-01
Quarterly
2016-06-29
$0.38
2016-07-01
2016-08-01
Quarterly
2016-03-30
$0.38
2016-04-01
2016-05-02
Quarterly
2015-12-30
$0.38
2016-01-04
2016-02-01
Quarterly
2015-09-30
$0.37
2015-10-02
2015-11-02
Quarterly
2015-07-01
$0.37
2015-07-06
2015-08-03
Quarterly
2015-04-01
$0.37
2015-04-06
2015-05-01
Quarterly
2014-12-30
$0.37
2015-01-02
2015-02-02
Quarterly
2014-10-01
$0.36
2014-10-03
2014-11-03
Quarterly
2014-07-01
$0.36
2014-07-03
2014-08-01
Quarterly
2014-04-02
$0.36
2014-04-04
2014-05-01
Quarterly
2013-12-31
$0.36
2014-01-03
2014-02-03
Quarterly
2013-10-02
$0.35
2013-10-04
2013-11-01
Quarterly
2013-07-02
$0.35
2013-07-05
2013-08-01
Quarterly
2013-04-03
$0.35
2013-04-05
2013-05-01
Quarterly
2013-01-02
$0.35
2013-01-04
2013-02-01
Quarterly
2012-10-03
$0.34
2012-10-05
2012-11-01
Quarterly
2012-07-03
$0.34
2012-07-06
2012-08-01
Quarterly
2012-04-03
$0.34
2012-04-05
2012-05-01
Quarterly
2012-01-04
$0.34
2012-01-06
2012-02-01
Quarterly
2011-10-06
$0.33
2011-10-11
2011-11-01
Quarterly
2011-06-29
$0.33
2011-07-01
2011-08-01
Quarterly
2011-03-30
$0.33
2011-04-01
2011-05-02
Quarterly
2011-01-05
$0.33
2011-01-07
2011-02-01
Quarterly
2010-09-29
$0.32
2010-10-01
2010-11-01
Quarterly
2010-06-30
$0.32
2010-07-02
2010-08-02
Quarterly
2010-03-30
$0.32
2010-04-04
2010-05-03
Quarterly
2009-12-30
$0.32
2010-01-04
2010-02-01
Quarterly
2009-09-30
$0.31
2009-10-02
2009-11-02
Quarterly
2009-07-01
$0.31
2009-07-06
2009-08-03
Quarterly
2009-04-01
$0.31
2009-04-03
2009-05-01
Quarterly
2008-12-30
$0.31
2009-01-02
2009-02-02
Quarterly
2008-10-01
$0.31
2008-10-03
2008-11-03
Quarterly
2008-07-02
$0.31
2008-07-07
2008-08-01
Quarterly
2008-04-02
$0.31
2008-04-04
2008-05-01
Quarterly
2008-01-02
$0.31
2008-01-04
2008-02-01
Quarterly
2007-10-03
$0.28
2007-10-05
2007-11-01
Quarterly
2007-07-03
$0.28
2007-07-06
2007-08-01
Quarterly
2007-04-03
$0.28
2007-04-06
2007-05-01
Quarterly
2007-01-03
$0.28
2007-01-05
2007-02-01
Quarterly
Insider trades
Date
Insider
Action
Shares
Price
Value
2026-11-05
Haller Julia A
Sell
3.80K
$63.31
240.58K
2026-11-03
Lenkowsky Adam
Buy
7.52K
—
—
2026-11-03
Lenkowsky Adam
Sell
3.85K
$61.71
237.46K
2026-11-03
Lenkowsky Adam
Sell
7.52K
—
—
2026-11-01
BOERNER CHRISTOPHER S.
Buy
406
—
—
2026-11-01
BOERNER CHRISTOPHER S.
Buy
2.96K
—
—
2026-11-01
BOERNER CHRISTOPHER S.
Sell
1.72K
$62.48
107.72K
2026-11-01
BOERNER CHRISTOPHER S.
Sell
2.96K
—
—
2026-11-01
Shanahan Karin
Buy
6.28K
—
—
2026-11-01
Shanahan Karin
Sell
3.21K
$62.48
200.75K
2026-11-01
Shanahan Karin
Sell
6.28K
—
—
2026-11-01
Meyers Gregory Scott
Buy
6.28K
—
—
2026-11-01
Meyers Gregory Scott
Sell
2.67K
$62.48
166.51K
2026-11-01
Meyers Gregory Scott
Sell
6.28K
—
—
2026-10-02
Gallman Cari
Buy
4.56K
—
—
2026-10-02
Gallman Cari
Sell
2.33K
$61.15
142.60K
2026-10-02
Gallman Cari
Sell
4.56K
—
—
2026-09-30
YALE PHYLLIS R
Buy
561
$62.40
35.00K
2026-09-30
Samuels Theodore R. II
Buy
821
$62.40
51.25K
2026-09-30
Rice Derica W
Buy
621
$62.40
38.75K
2026-09-30
McMullen Michael R.
Buy
561
—
—
2026-09-30
Arduini Peter J
Buy
561
—
—
2026-09-09
Massacesi Cristian
Sell
6.25K
$64.57
403.50K
2026-09-01
Short Bartie Wendy
Buy
1.24K
$66.92
82.71K
2026-09-01
Short Bartie Wendy
Sell
633
$66.92
42.36K
2026-09-01
Short Bartie Wendy
Sell
1.24K
—
—
2026-08-25
Holzer Phil M
Sell
500
$67.50
33.75K
2026-08-01
Massacesi Cristian
Sell
51.17K
—
—
2026-08-01
Massacesi Cristian
Buy
51.17K
—
—
2026-08-01
Massacesi Cristian
Sell
26.18K
$65.31
1.71M
2026-08-01
Gallman Cari
Buy
1.06K
—
—
2026-08-01
Gallman Cari
Sell
543
$65.31
35.46K
2026-08-01
Gallman Cari
Sell
1.06K
—
—
2026-06-30
YALE PHYLLIS R
Buy
607
—
—
2026-06-30
Samuels Theodore R. II
Buy
889
—
—
2026-06-30
Rice Derica W
Buy
673
—
—
2026-06-30
McMullen Michael R.
Buy
607
—
—
2026-06-30
Arduini Peter J
Buy
607
—
—
2026-06-15
Haller Julia A
Buy
20.46K
$53.76
1.10M
2026-06-15
Haller Julia A
Sell
20.46K
$53.76
1.10M
2026-06-03
Short Bartie Wendy
Buy
8.04K
—
—
2026-06-03
Short Bartie Wendy
Sell
3.88K
$54.72
212.09K
2026-06-03
Short Bartie Wendy
Sell
8.04K
—
—
2026-05-01
Lenkowsky Adam
Buy
1.37K
—
—
2026-05-01
Lenkowsky Adam
Sell
203
—
—
2026-05-01
Lenkowsky Adam
Sell
599
$58.22
34.87K
2026-05-01
Lenkowsky Adam
Sell
1.37K
—
—
2026-04-01
Shanahan Karin
Buy
3.31K
—
—
2026-04-01
Shanahan Karin
Sell
1.69K
$61.73
104.45K
2026-04-01
Shanahan Karin
Sell
3.31K
—
—
2026-04-01
Elkins David V
Sell
25.52K
$61.60
1.57M
2026-04-01
Elkins David V
Sell
4.48K
$62.05
278.05K
2026-03-31
YALE PHYLLIS R
Buy
577
—
—
2026-03-31
Samuels Theodore R. II
Buy
845
—
—
2026-03-31
Rice Derica W
Buy
639
—
—
2026-03-31
McMullen Michael R.
Buy
577
—
—
2026-03-31
Arduini Peter J
Buy
577
—
—
2026-03-10
Hickey Benjamin
Buy
17.14K
—
—
2026-03-10
Hickey Benjamin
Buy
11.43K
—
—
2026-03-10
Shibutani Hiroshi Chris
Buy
11.76K
—
—
2026-03-10
Shibutani Hiroshi Chris
Buy
7.84K
—
—
2026-03-10
Massacesi Cristian
Buy
39.18K
—
—
2026-03-10
Massacesi Cristian
Buy
26.12K
—
—
2026-03-10
Short Bartie Wendy
Buy
4.50K
—
—
2026-03-10
Short Bartie Wendy
Buy
9.80K
—
—
2026-03-10
Short Bartie Wendy
Sell
2.21K
—
—
2026-03-10
Short Bartie Wendy
Sell
828
$60.13
49.79K
2026-03-10
Short Bartie Wendy
Buy
749
—
—
2026-03-10
Short Bartie Wendy
Sell
81
—
—
2026-03-10
Short Bartie Wendy
Buy
6.53K
—
—
2026-03-10
Short Bartie Wendy
Sell
242
$60.13
14.55K
2026-03-10
Short Bartie Wendy
Buy
639
—
—
2026-03-10
Short Bartie Wendy
Sell
72
—
—
2026-03-10
Short Bartie Wendy
Sell
205
$60.13
12.33K
2026-03-10
Short Bartie Wendy
Sell
749
—
—
2026-03-10
Short Bartie Wendy
Sell
639
—
—
2026-03-10
Short Bartie Wendy
Sell
4.50K
—
—
2026-03-10
Shanahan Karin
Buy
19.76K
—
—
2026-03-10
Shanahan Karin
Buy
31.84K
—
—
2026-03-10
Shanahan Karin
Sell
9.70K
—
—
2026-03-10
Shanahan Karin
Sell
5.14K
$60.13
309.37K
2026-03-10
Shanahan Karin
Buy
21.22K
—
—
2026-03-10
Shanahan Karin
Buy
3.29K
—
—
2026-03-10
Shanahan Karin
Sell
356
—
—
2026-03-10
Shanahan Karin
Sell
1.50K
$60.13
90.38K
2026-03-10
Shanahan Karin
Buy
2.45K
—
—
2026-03-10
Shanahan Karin
Sell
275
—
—
2026-03-10
Shanahan Karin
Sell
1.11K
$60.13
66.86K
2026-03-10
Shanahan Karin
Sell
3.29K
—
—
2026-03-10
Shanahan Karin
Sell
2.45K
—
—
2026-03-10
Shanahan Karin
Sell
19.76K
—
—
2026-03-10
Plenge Robert M
Buy
14.05K
—
—
2026-03-10
Plenge Robert M
Buy
26.94K
—
—
2026-03-10
Plenge Robert M
Sell
6.90K
—
—
2026-03-10
Plenge Robert M
Sell
3.17K
$60.13
190.73K
2026-03-10
Plenge Robert M
Buy
2.34K
—
—
2026-03-10
Plenge Robert M
Sell
253
—
—
2026-03-10
Plenge Robert M
Buy
17.96K
—
—
2026-03-10
Plenge Robert M
Sell
927
$60.13
55.74K
2026-03-10
Plenge Robert M
Buy
1.11K
—
—
Institutional holders
Latest filed quarter: Q3 2026.
Institutions holding: 2.30K, holders -337 vs prior quarter. Ownership 59.55%.